SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 83.89 |
| Enterprise Value ($M) | 77.79 |
| Book Value ($M) | 33.09 |
| Book Value / Share | 0.97 |
| Price / Book | 2.54 |
| NCAV ($M) | 28.79 |
| NCAV / Share | 0.84 |
| Price / NCAV | 2.91 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.79 |
| Return on Assets (ROA) | -0.81 |
| Return on Equity (ROE) | -1.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.47 |
| Current Ratio | 6.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 35.97 |
| Assets | 40.27 |
| Liabilities | 7.18 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Highbridge Capital Management Llc | 6.80 | ||
| 13G/A | Szalay Aladar | 9.90 | -18.44 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 59,746 | 190,378 | 31.38 | |
| 48,721 | 159,799 | 30.49 | |
| 62,135 | 179,955 | 34.53 | |
| 82,964 | 294,225 | 28.20 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLMD – Galmed Pharmaceuticals Ltd. | GLSI – Greenwich LifeSciences, Inc. |
| GLTO – Galecto, Inc. | GNPX – Genprex, Inc. |
| GOVX – GeoVax Labs, Inc. |
Financial data and stock pages provided by
Fintel.io